Two antibody therapies for COVID-19 from Eli Lilly now undergoing testing may be authorised for use as soon as September, as reported in London South East.
However, the news source noted that administering the drugs was complex and manufacturing capacity limited.
Meanwhile, Chief scientific officer Daniel Skovronsky said that a third such treatment may enter clinical trials in the coming weeks.
These monocloal antibodies are designed for use specifically against SARS-CoV-2, but are already used to treat cancer and rheumatoid arthritis, among other diseases.
The key will be whether by August or September people treated with them are able to avoid hospitalisation, which could lead to their authorisation for immediate use. "So that puts you in the fall time...September, October, November is not unreasonable," Skovronsky said.
Eli Lilly was working with AbCellera on one of the antibodies, LY-Cov555, and on another, JS016, with Junshi Biosciences.
To read more NewsPoints articles, click here.